We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low Serum Glutathione Peroxidase Activity Increases Risk of Cardiovascular Disease in Individuals with Low HDL-cholesterol

By LabMedica International staff writers
Posted on 28 Jun 2012
Print article
A retrospective study of stored serum samples has found that individuals with low HDL-cholesterol (cholesterol associated with high-density lipoproteins) and low levels of the enzyme glutathione peroxidase (GPx3) suffered significantly more incidence of fatal cardiovascular disease than did those with low HDL-cholesterol but elevated levels of GPx3.

GPx3 is a natural antioxidant that contains a selenocysteine (Sec) residue at its active site. One of its activities in the body is to reduce oxidized lipids, such as LDL (low-density lipoproteins), which have been linked to the development of atherosclerosis. This relationship to cardiovascular disease was the basis for a study conducted by investigators at the University of Minnesota (Minneapolis, USA) to determine whether high GPx3 activity could reduce cardiovascular disease (CVD) mortality.

The investigators evaluated 130 stored serum samples obtained during the Minnesota Heart Survey from participants aged 26-85 years who had died of cardiovascular disease after five to 12 years of follow-up care. Odds ratios (OR) were calculated after adjustment for age, sex, baseline year, body mass index, smoking, alcohol intake, physical activity, total and HDL-cholesterols, systolic blood pressure, serum glucose, and gamma glutamyltransferase (GTT) activity. Data was compared to that from 240 control samples from individuals without cardiovascular disease.

Results published in the June 15, 2012, online edition of the journal PLoS One revealed that individuals with low levels of HDL-cholesterol and GPx3 were six times more likely to die from cardiovascular disease, including heart attack or stroke, than those with low levels of HDL-cholesterol and high levels of GPx3. GPx3 levels were not linked significantly to risk of cardiovascular disease in individuals with high levels of HDL-cholesterol.

“In our study, we found that people with high levels of the GPx3 enzyme and low levels of good cholesterol were six times less likely to develop cardiovascular disease than people with low levels of both,” said senior author Dr. Jordan L. Holtzman, professor of pharmacology and medicine at the University of Minnesota. “This GPx3 enzyme gives us a good reason to believe that natural antioxidants like GPx3 are good for heart health. This is an important enzyme for people with low HDL-cholesterol. We think further research will be important in determining the future role of GPx3 and what drugs may serve to increase its activity in the blood.”

"It is important to point out that people should not rush out to their doctors and demand testing for the GPx3 enzyme,” said Dr. Holtzman. “But in time, we hope that measuring this enzyme will be a common blood test when determining whether a patient is at risk for cardiovascular disease, including heart attacks and strokes.”

Related Links:

University of Minnesota


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.